AGIO
Price
$27.56
Change
-$0.88 (-3.09%)
Updated
Apr 3, 02:28 PM (EDT)
Capitalization
1.63B
28 days until earnings call
INSM
Price
$73.50
Change
+$0.06 (+0.08%)
Updated
Apr 3, 02:44 PM (EDT)
Capitalization
13.29B
28 days until earnings call
Ad is loading...

AGIO vs INSM

Header iconAGIO vs INSM Comparison
Open Charts AGIO vs INSMBanner chart's image
Agios Pharmaceuticals
Price$27.56
Change-$0.88 (-3.09%)
Volume$100
Capitalization1.63B
Insmed
Price$73.50
Change+$0.06 (+0.08%)
Volume$2.92K
Capitalization13.29B
AGIO vs INSM Comparison Chart
Loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AGIO vs. INSM commentary
Apr 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGIO is a Hold and INSM is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 03, 2025
Stock price -- (AGIO: $28.44 vs. INSM: $73.44)
Brand notoriety: AGIO and INSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGIO: 141% vs. INSM: 133%
Market capitalization -- AGIO: $1.63B vs. INSM: $13.29B
AGIO [@Biotechnology] is valued at $1.63B. INSM’s [@Biotechnology] market capitalization is $13.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $308.32B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGIO’s FA Score shows that 1 FA rating(s) are green whileINSM’s FA Score has 1 green FA rating(s).

  • AGIO’s FA Score: 1 green, 4 red.
  • INSM’s FA Score: 1 green, 4 red.
According to our system of comparison, both AGIO and INSM are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGIO’s TA Score shows that 4 TA indicator(s) are bullish while INSM’s TA Score has 4 bullish TA indicator(s).

  • AGIO’s TA Score: 4 bullish, 6 bearish.
  • INSM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, INSM is a better buy in the short-term than AGIO.

Price Growth

AGIO (@Biotechnology) experienced а -6.45% price change this week, while INSM (@Biotechnology) price change was -4.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.69%. For the same industry, the average monthly price growth was -9.74%, and the average quarterly price growth was -14.08%.

Reported Earning Dates

AGIO is expected to report earnings on May 01, 2025.

INSM is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-7.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
INSM($13.3B) has a higher market cap than AGIO($1.63B). INSM YTD gains are higher at: 6.373 vs. AGIO (-13.451). AGIO has higher annual earnings (EBITDA): -420.08M vs. INSM (-818.79M). INSM has more cash in the bank: 1.43B vs. AGIO (894M). AGIO has less debt than INSM: AGIO (57M) vs INSM (1.15B). INSM has higher revenues than AGIO: INSM (364M) vs AGIO (36.5M).
AGIOINSMAGIO / INSM
Capitalization1.63B13.3B12%
EBITDA-420.08M-818.79M51%
Gain YTD-13.4516.373-211%
P/E Ratio2.44N/A-
Revenue36.5M364M10%
Total Cash894M1.43B62%
Total Debt57M1.15B5%
FUNDAMENTALS RATINGS
AGIO vs INSM: Fundamental Ratings
AGIO
INSM
OUTLOOK RATING
1..100
6977
VALUATION
overvalued / fair valued / undervalued
1..100
42
Fair valued
87
Overvalued
PROFIT vs RISK RATING
1..100
10018
SMR RATING
1..100
18100
PRICE GROWTH RATING
1..100
8440
P/E GROWTH RATING
1..100
87100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AGIO's Valuation (42) in the Biotechnology industry is somewhat better than the same rating for INSM (87). This means that AGIO’s stock grew somewhat faster than INSM’s over the last 12 months.

INSM's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for AGIO (100). This means that INSM’s stock grew significantly faster than AGIO’s over the last 12 months.

AGIO's SMR Rating (18) in the Biotechnology industry is significantly better than the same rating for INSM (100). This means that AGIO’s stock grew significantly faster than INSM’s over the last 12 months.

INSM's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for AGIO (84). This means that INSM’s stock grew somewhat faster than AGIO’s over the last 12 months.

AGIO's P/E Growth Rating (87) in the Biotechnology industry is in the same range as INSM (100). This means that AGIO’s stock grew similarly to INSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGIOINSM
RSI
ODDS (%)
Bullish Trend 1 day ago
54%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
76%
Bearish Trend 1 day ago
75%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
71%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
74%
Bearish Trend 1 day ago
73%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 7 days ago
72%
Declines
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 3 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
66%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
79%
View a ticker or compare two or three
Ad is loading...
AGIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JNRFX77.980.59
+0.76%
Janus Henderson Research D
VCRIX13.970.09
+0.65%
NYLI CBRE Global Infrastructure Class I
PICRX39.98N/A
N/A
Putnam International Capital Opp R
GEMUX23.73N/A
N/A
Goldman Sachs Emerging Markets Eq R6
RAAAX10.23N/A
N/A
Altegris/AACA Opportunistic Real Estt A

AGIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGIO has been loosely correlated with AXON. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if AGIO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGIO
1D Price
Change %
AGIO100%
+3.80%
AXON - AGIO
45%
Loosely correlated
+3.18%
OLMA - AGIO
44%
Loosely correlated
-0.30%
INSM - AGIO
44%
Loosely correlated
+2.00%
CORT - AGIO
41%
Loosely correlated
-8.83%
RAPT - AGIO
41%
Loosely correlated
-0.85%
More

INSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, INSM has been closely correlated with THAR. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if INSM jumps, then THAR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INSM
1D Price
Change %
INSM100%
+2.00%
THAR - INSM
74%
Closely correlated
+0.78%
SRPT - INSM
44%
Loosely correlated
+0.90%
AGIO - INSM
43%
Loosely correlated
+3.80%
VERA - INSM
41%
Loosely correlated
+7.13%
AXON - INSM
40%
Loosely correlated
+3.18%
More